Iovance Biotherapeutics Appoints Jean-Marc Bellemin as Main Economic Officer Nasdaq:IOVA

SAN CARLOS, Calif., Dec. 14, 2020 (World NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology enterprise building novel T mobile-dependent cancer immunotherapies, currently declared the appointment of Jean-Marc Bellemin as Chief Economical Officer, successful these days. Mr. Bellemin delivers 27 many years of business expertise in finance, which includes community businesses.

“I am quite pleased to welcome Jean-Marc to Iovance in the course of these kinds of an essential time for the Organization,” mentioned Maria Fardis, Ph.D., President and Main Govt Officer of Iovance Biotherapeutics. “Jean-Marc has extensive experience as a CFO in community biopharma businesses with commercial merchandise and with a world footprint, as properly as an being familiar with of cell therapy merchandise. His skills are nicely aligned with Iovance’s plans and directions.”

Mr. Bellemin has 27 yrs of progressive global encounter in finance, small business leadership and functions management within start off-up and worldwide multi-billion-dollar corporations. Most just lately he served as Government Vice President and Main Fiscal Officer of Gritstone Oncology, the place he led the all round fiscal approach and a number of private and public financings, together with an first public providing and to start with equity follow-on financing. Previously Mr. Bellemin held roles of escalating duty at Actelion Prescribed drugs, from 2002 till the 2017 acquisition by Johnson & Johnson. As Senior Vice President and Chief Economic Officer, Head of Finance and Market Accessibility at Actelion Pharmaceuticals US Inc., he delivered strategic management, operations, and fiscal management. Mr. Bellemin was actively involved in the start of 6 prescription drugs inside of 5 years, which includes a few ‘blockbusters’ drugs, helping push Actelion US to $1.8 billion in revenue.

“I am very psyched to be part of Iovance and help lead the critical transition toward bringing TIL to patients in a business environment,” claimed Mr. Bellemin. “I feel TIL mobile remedy is a accurate platform with the likely to deal with a lot of hundreds of most cancers people in multiple indications throughout the environment. I look forward to providing my knowledge in international finance and business functions to help create worth for individuals and medical professionals, as effectively as Iovance shareholders.”

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics aims to strengthen client care by creating T cell-centered immunotherapies broadly obtainable for the procedure of individuals with sound tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy employs a patient’s possess immune cells to attack cancer. TIL cells are extracted from a patient’s possess tumor tissue, expanded by way of a proprietary method, and infused back into the individual. Upon infusion, TIL attain tumor tissue, the place they attack most cancers cells. The organization has finished dosing in the pivotal analyze in sufferers with metastatic melanoma and cervical. In addition, the company’s TIL treatment is being investigated for the procedure of people with locally state-of-the-art, recurrent or metastatic cancers together with head and neck and non-little cell lung most cancers. A medical analyze to investigate Iovance T mobile therapy for blood cancers named peripheral blood lymphocyte (PBL) remedy is open to enrollment. For more facts, be sure to stop by www.iovance.com.

Ahead-Searching Statements

Sure issues mentioned in this press launch are “forward-seeking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) inside of the indicating of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). All these types of created or oral statements created in this press launch, other than statements of historical simple fact, are forward-looking statements and are intended to be protected by the safe harbor for ahead-hunting statements delivered by the PSLRA. Without the need of restricting the foregoing, we may perhaps, in some circumstances, use terms these kinds of as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “could,” “might,” “will,” “should” or other terms that express uncertainty of upcoming situations or outcomes and are supposed to recognize ahead-wanting statements. Forward-wanting statements are based on assumptions and assessments created in mild of management’s experience and notion of historic developments, latest conditions, envisioned future developments and other components considered to be correct. Forward-on the lookout statements in this press launch are produced as of the date of this push launch, and we undertake no duty to update or revise any these kinds of statements, no matter whether as a consequence of new details, future situations or normally. Forward-seeking statements are not ensures of long term overall performance and are subject to hazards, uncertainties and other things, lots of of which are exterior of our regulate, that may trigger actual final results, concentrations of exercise, functionality, achievements and developments to be materially different from people expressed in or implied by these ahead-seeking statements. Significant aspects that could result in true benefits, developments and small business decisions to differ materially from ahead-on the lookout statements are explained in the sections titled “Risk Factors“ in our filings with the Securities and Exchange Commission, like our most latest Yearly Report on Variety 10-K and Quarterly Studies on Variety 10-Q, and include things like, but are not minimal to, the next considerable acknowledged and unidentified threats and uncertainties inherent in our enterprise: the outcomes of the COVID-19 pandemic risks connected to the timing of and our means to efficiently create, submit, acquire and maintain U.S. Food stuff and Drug Administration (“FDA”) or other regulatory authority acceptance of, or other motion with regard to, our product candidates, and our skill to correctly commercialize any product or service candidates for which we attain Fda approval preliminary and interim medical benefits, which could include efficacy and safety final results, from ongoing scientific trials may possibly not be reflected in the ultimate analyses of our ongoing medical trials or subgroups in just these trials the hazard that enrollment may possibly have to have to be adjusted for our trials and cohorts within just those trials dependent on Fda and other regulatory company enter the new edition of the protocol which additional defines the patient inhabitants to incorporate extra state-of-the-art clients in our cervical most cancers demo could have an adverse outcome on the outcomes claimed to date the chance that we may perhaps be essential to conduct added medical trials or modify ongoing or long run clinical trials primarily based on feed-back from the Fda or other regulatory authorities the threat that our interpretation of the success of our medical trials or communications with the Fda may well vary from the interpretation of such final results or communications by the Food and drug administration the acceptance by the market place of our product candidates and their opportunity reimbursement by payors, if authorised our capacity or inability to manufacture our therapies employing third get together brands or our personal facility could adversely have an affect on our probable industrial start the benefits of medical trials with collaborators working with distinct producing procedures might not be reflected in our sponsored trials the hazard that unanticipated costs could minimize our approximated dollars balances and increase our estimated cash specifications and other factors, including normal economic conditions and regulatory developments, not inside of our control.

CONTACTS

Iovance Biotherapeutics, Inc:
Sara Pellegrino, IRC
Vice President, Trader Relations & Public Relations
650-260-7120 ext. 264
[email protected]

Solebury Trout:
Chad Rubin (traders)
646-378-2947
[email protected]

Abundant Allan (media)
646-378-2958
[email protected]